25 Intuitions About Cancer: A Layperson's Thought Experiments, Mapped to the Research Frontier

Introduction

This essay records twenty-five thought experiments that I, a person with no formal training in medicine, freely generated about the problem of cancer. Each thought began as a rough intuition, and only afterward did I trace which field of the scientific literature it touched.

Of the twenty-five, twenty-three turned out to correspond precisely to fields that academia is actively pursuing, and in some cases the frame I arrived at was, at the level of vocabulary, nearly identical to the frame being pursued in ongoing clinical trials.

The remaining two were narrow variants I could not find as explicit clinical programs, and I have placed them at the front of this essay as proposals rather than observations.

The purpose of this essay is to record how free thought from outside a specialized field can intersect with its frontier, and to use the pattern of that intersection to test a hypothesis about how such thought can now function.

Cancer is one of the largest unsolved problems humanity is carrying. As one citizen, I believe that documenting my own thought rather than letting it dissipate — even for the sake of a single idea — is worth doing. The Korean expression hongik ingan (弘益人間), meaning “to broadly benefit the human world,” is the closest description of what motivated this writing.

Two Proposals — Narrow Variants

The two items below are cases where the broad version of the intuition is clearly present in the literature, but the narrow variant I arrived at does not appear as an explicit clinical program in my search.

Proposal 1. Tumor Dormancy Induction via Normal Fibroblast Cell Therapy

Starting observation.

The phenomenon of “neighbor suppression” — in which normal fibroblasts in the tumor microenvironment inhibit the growth of adjacent transformed cells — has been known since 1966. The field of Cancer-Associated Fibroblasts (CAFs) has established how peri-tumoral fibroblasts are converted into a tumor-friendly state, and the finding that type III collagen secreted by normal fibroblasts keeps disseminated cancer cells in dormancy has been demonstrated in a series of papers including the 2022 Nature Cancer paper from the Bravo-Cordero group.

Current mainstream approaches.

First, CAF depletion (e.g., FAP-targeting CAR-T). Second, CAF reprogramming (pirfenidone, all-trans retinoic acid, vitamin D, Am80, meflin induction, etc.). Third, direct injection of recombinant type III collagen protein or hydrogels. Fourth, CAF normalization (induced return to a dormancy-supporting state).

The narrow variant proposed here.

An approach in which living fibroblasts — derived from normal donors or from the patient’s own tissue — are directly injected as a cell therapy product into the tumor periphery or into sites where disseminated cancer cells exist, in order to actively reconstitute a dormancy-supporting microenvironment.

Adjacent facts that ground this.

Autologous fibroblast cell therapy is already FDA-approved under the name LAVIV (Fibrocell Science), but its current indication is cosmetic (improvement of nasolabial fold lines), not oncology. Type III collagen protein injection and CAF reprogramming are each independently in clinical or preclinical development. However, the combination of the two — using living normal fibroblasts themselves as a dormancy-inducing cell therapy product — does not appear in my search as an explicit clinical program.

Open questions.

Can injected normal fibroblasts maintain their normal state in the tumor microenvironment without converting into CAFs? Would CRISPR-enhanced type III collagen secretion amplify the effect? Which tumor types — particularly dormant cancer cells at metastatic sites — would be the best fit? This variant is a new combination of two existing fields, and if translated into the clinic it would carry the advantage of low immune rejection risk due to autologous cell use.

Proposal 2. Autologous Tissue Isolation Barrier for Unresectable Tumors

Starting observation.

It has long been recorded in surgical pathology that some tumors are naturally surrounded by a fibrous capsule and progress more slowly or recur less often. For example, patients with naturally encapsulated colorectal liver metastases have notably lower recurrence rates. The field of tumor encapsulation has explored wrapping tumors in polymers (chitosan, alginate, cellulose) or other exogenous materials.

Current mainstream approaches.

First, pharmacological approaches that strengthen natural fibrous capsule formation. Second, polymer-based tumor encapsulation using synthetic external materials. Third, autologous Adipose Manipulation Transplantation (AMT), reported in Nature Biotechnology in 2025; however, AMT works primarily through nutrient competition rather than isolation. Fourth, surgical autologous tissue transplantation — DIEP, TRAM, TUG, LTP, TFL flaps — which are all used for reconstruction after tumor resection, not for isolating unresectable tumors.

The narrow variant proposed here.

An approach that uses the patient’s own autologous tissue — periosteum, fascia, muscle, or bone fragments — to physically surround and isolate an unresectable primary tumor or micrometastatic site. Rather than removing the tumor directly, the strategy is to contain it within the patient’s own tissue, which carries no immune rejection risk, thereby blocking the physical route of invasion and metastasis.

Adjacent facts that ground this.

Autologous free flap surgery has been a standard surgical technique for over a century and is routinely performed in head and neck cancer, breast cancer, and abdominal wall malignancies. The clinical data from naturally encapsulated colorectal liver metastases show that tumor isolation produces clinically meaningful outcomes. However, I could not find a clinical program that uses autologous tissue explicitly for active isolation of unresectable tumors.

Open questions.

Would an autologous tissue capsule around a tumor cut off its blood supply, or would it provide new vasculature? Is the mechanical strength of periosteum or fascia sufficient to contain invasive pressure? Could this approach be applied to tumors with low resectability rates, such as pancreatic cancer? This variant combines the surgical community’s long-standing autologous tissue transplantation techniques with the clinical value of tumor isolation as a new indication.

23 Intuitions — A Layperson’s Thoughts and Humanity’s Answers

The twenty-three items below are listed in the order I first thought of them. Each entry contains the original rough intuition, the reasoning behind it, and the corresponding field of research and its stage of progress.

Intuition 1. Can we not simply rebuild and replace the damaged organ?

Cancer is, in the end, a failure of the cells of a specific organ. If a damaged organ could be replaced with a new one entirely, then a path opens up that addresses the damage cancer has caused rather than cancer itself. If the new organ can be built from the patient’s own cells, there is no immune rejection.

Corresponding field: induced pluripotent stem cells (iPSCs) and regenerative organ medicine. In 2006, Shinya Yamanaka discovered the four transcription factors (OCT4, SOX2, KLF4, c-MYC) that return adult cells to a pluripotent state, opening the path to producing any type of cell from a patient’s own skin. Anthony Atala’s group at Wake Forest has successfully transplanted bladders, urethras, and vaginas built from patients’ own cells into human recipients. Juan Carlos Izpisua Belmonte’s work has shown the possibility of rejuvenating aged tissue through partial reprogramming in animal models. Multiple clinical trials on pancreatic islet cells, retina, and myocardium are in progress.

Intuition 2. Can division be selectively controlled?

The essence of cancer is uncontrolled division. If division itself could be selectively slowed or halted — not in all cells, but only in the ones dividing abnormally — then the disease could be managed without killing the cancer cells.

Corresponding field: cyclin-dependent kinase (CDK) inhibitors. Palbociclib (Ibrance), a CDK4/6 inhibitor, received FDA approval in 2015 and has become the standard of care for hormone receptor-positive advanced breast cancer. Ribociclib and abemaciclib are also approved in the same class. These agents arrest cancer cells at the G1 phase of the cell cycle while having relatively limited effect on normal cells. The intuition is already realized as a mainstream class of clinical drugs.

Intuition 3. What if there were a recording device to trace the origin of cancer backward in time?

When a program misbehaves, you read its debug log. If there were a device inside the cell that recorded events in temporal order, it would be possible to retrospectively trace which change at which moment drove the transition into cancer.

Corresponding field: molecular recorders, CRISPR-based cell lineage tracing. David Liu’s group at the Broad Institute has developed prime-editing-based molecular recording systems (CAMERA, DOMINO), and Randall Platt’s group at ETH Zürich has repurposed the CRISPR-Cas9 system itself as a tool for writing cellular events into DNA. The groups of Jay Shendure and Michael Elowitz have published methods that reconstruct the complete lineage of every cell in a tumor through accumulated DNA changes across cell divisions. The field is enabling a time-resolved understanding of tumor evolution.

Intuition 4. Can a cell’s healthy state be backed up and later restored?

On a computer, you save the state at some point in time and roll back to it when problems arise. What if the healthy state of a cell could be backed up in some form, and when cancer arises, the cell could be restored to that backup state?

Corresponding field: partial reprogramming, cellular rejuvenation. The 2016 Cell paper from the Belmonte group showed that cyclic, partial expression of the Yamanaka factors reversed hallmarks of aging in mice. Altos Labs is a $3 billion company built around this field, and many of the key researchers, including Belmonte, have joined. The approach is now being studied for aging reversal, tissue regeneration, and potentially the normalization of cancer cells.

Intuition 5. Selective reset — can one system be reset without touching the others?

You don’t reinstall the entire operating system to reset a single program. What if, instead of reprogramming the whole cell, only the specific epigenetic changes that led to cancer could be selectively undone?

Corresponding field: targeted epigenetic reprogramming, partial epigenetic rejuvenation. This is a precise subfield of partial reprogramming from Intuition 4. Tools that fuse catalytically inactive dCas9 with epigenetic editing domains (dCas9-DNMT3A, dCas9-TET1) are being used to selectively manipulate the methylation state of specific genes. Such precise epigenetic editing opens the possibility of targeting only the abnormal expression patterns of cancer cells for reversion.

Intuition 6. Can normal cells be made to outcompete abnormal ones?

When healthy and abnormal cells coexist in a tissue, if the healthy cells could be given a competitive advantage, the abnormal cells would be outcompeted and naturally eliminated. Not killed — crowded out.

Corresponding field: cell competition. The phenomenon of cell competition was first observed in Drosophila by Morata and Ripoll in 1975. Eduardo Moreno’s group at the Champalimaud Centre in Lisbon and Yasuyuki Fujita’s group at Kyoto University extended it into mammalian systems. One of the key findings is that isoforms of the Flower protein — Flower-Win and Flower-Lose — serve as molecular tags indicating whether a cell has higher or lower fitness than its neighbors. Epithelial Defense Against Cancer (EDAC) describes the phenomenon in which normal epithelial cells actively extrude transformed cells from the tissue.

Intuition 7. Can the immune system be made to mistake cancer cells for outside invaders?

The reason the immune system fails to clear cancer is that cancer cells are the body’s own. If something could be attached to cancer cells that made the immune system recognize them as viruses or bacteria, the immune system itself would eliminate them.

Corresponding field: oncolytic virus therapy, tumor microenvironment immune activation. T-VEC (Imlygic, talimogene laherparepvec), the first FDA-approved oncolytic virus (2015), is a modified herpes simplex virus injected directly into melanoma lesions. The virus replicates inside cancer cells, destroying them while also expressing GM-CSF to trigger an immune response. As a result, the tumor appears to the immune system as an infected tissue, and the immune system mounts a full attack. Many other oncolytic virus candidates are in clinical trials.

Intuition 8. Is there no systemic approach to cleansing the entire body?

Instead of attacking a local tumor, is there an approach that changes the whole-body environment — vasculature, nutrient supply, waste removal — into a state where cancer cannot thrive?

Corresponding field: vascular normalization, metabolic therapy, senolytics. Rakesh K. Jain’s work at Harvard / Massachusetts General Hospital showed that normalizing tumor vasculature improves drug delivery and increases immune cell infiltration. This is not simply blocking blood vessels, but returning abnormal tumor vasculature toward a normal pattern. Thomas Seyfried’s ketogenic metabolic therapy targets the glucose dependence of cancer cells. Mayo Clinic’s senolytics research targets senescent cells for selective elimination, aiming to alter the environment in which cancer arises.

Intuition 9. Could the nervous system be a higher-level controller of cancer?

Every system in the body has a higher-level control layer above it. If signals from the nervous system or hormones also act on cancer cell behavior, then manipulating the upstream signal might be more efficient than targeting cancer cells directly.

Corresponding field: cancer neuroscience. The field was formally launched in December 2019. The groups of Michelle Monje (Stanford) and Frank Winkler (Heidelberg) have shown that neural activity directly promotes glioma growth. That is, neural signals serve as a growth signal to the tumor. The finding has prompted investigation of anticonvulsants and neural signaling blockers as new cancer therapeutics. Numerous clinical trials targeting neuro-tumor interactions are underway.

Intuition 10. Can cancer be controlled by physical force?

Rather than drugs or radiation, can physical vibration or mechanical force be applied to cancer cells directly to control them?

Corresponding field: Tumor Treating Fields, High-Intensity Focused Ultrasound (HIFU), histotripsy. Novocure’s Optune system uses alternating electric fields to interfere with mitotic spindle formation in dividing tumor cells and received FDA approval for glioma in 2011. HIFU uses focused ultrasound to non-invasively heat and destroy tumor tissue. Histotripsy is a more recent technique that mechanically destroys tissue through acoustic cavitation; the FDA approved it for liver tumors in 2023. The intuition of “physical force” is instantiated in three distinct non-pharmacological physical approaches.

Intuition 11. Can cancer cells be placed in dormancy and kept there?

Perhaps not every cancer needs to be eradicated. If cancer cells can be kept asleep and never reactivated for the rest of a patient’s life, that is effectively a cure.

Corresponding field: cancer dormancy. Tumor dormancy was first clinically observed by Willis in 1934. The field acquired its modern molecular foundation through the work of Joan Massagué (Chief Scientific Officer at MSK), Julio Aguirre-Ghiso (formerly Albert Einstein, now at Mount Sinai), and Jose Javier Bravo-Cordero (Mount Sinai). The key finding is that disseminated cancer cells require specific microenvironmental signals to exit dormancy and reactivate, and that by manipulating those signals, dormancy can be deliberately maintained. Type III collagen was identified as a central player in dormancy maintenance.

Intuition 12. Can metastasis be blocked by crowding the target site with a friendly environment?

Metastasis requires a new site where the tumor can take root. If the new site is hostile to the tumor cell, or if it is already full of friendly normal cells so that there is no room for the tumor cell to settle, metastasis will not occur.

Corresponding field: tumor dormancy microenvironment manipulation and type III collagen therapy. The 2022 Nature Cancer paper from the Bravo-Cordero group demonstrated the central role of type III collagen in maintaining dormant cancer cells. Follow-up work (2024 npj Breast Cancer, among others) showed that co-injection of recombinant type III collagen protein as a hydrogel with tumor cells in mouse models suppressed both tumor growth and recurrence. Proposal 1 at the front of this essay is a narrow step beyond the existing approach in this field.

Intuition 13. What if the polarity of cancer cells were flipped?

Every epithelial cell has an up and a down, an inside and an outside. When this polarity breaks down, the cell no longer knows where it should be. If cancer cell polarity were forcibly flipped, invasion itself would become impossible.

Corresponding field: cell polarity, polarity-related tumor suppressors. The apical-basal polarity regulators Lgl, Dlg, and Scrib, originally identified in Drosophila, have been shown to function as tumor suppressors in mammals as well. Loss of these proteins is observed in diverse epithelial cancers. Polarity regulators such as LKB1 and Par4 are also directly connected to tumor suppressor function. The field pursues the question of whether restoring cell polarity can block the invasive capacity of cancer cells.

Intuition 14. What if cancer cells were made unable to sense where to go?

To move, a cell must sense the stiffness and softness of its environment. If this sensing ability is disrupted, the cancer cell cannot decide where to invade.

Corresponding field: mechanosensing and durotaxis blockade. The Mouneimne group’s 2019 work showed that the EVL protein plays a central role in the mechanosensing of breast cancer cells. The Caveolin-1 and YAP signaling pathways mediate how tumor cells detect and respond to environmental stiffness. The ROCK inhibitor Y-27632 is widely used as a tool to block mechanosensing. Durotaxis — the phenomenon in which cells migrate toward stiffer regions — and its inhibition has become one axis of anti-metastatic strategy.

Intuition 15. What if the physical structures used for invasion were removed?

When cancer cells invade other tissue, they use physical structures on their surface — protrusions that degrade the surrounding matrix. If those structures could be directly removed, invasion could not occur.

Corresponding field: invadopodia inhibition. Invadopodia are actin-based invasive structures formed by tumor cells that secrete matrix metalloproteinases (MMPs) and other proteolytic enzymes in concentrated fashion to degrade the surrounding extracellular matrix. Multiple kinases are involved in their formation, and some are already targets of FDA-approved drugs. Imatinib (Gleevec, Bcr-Abl), Nilotinib, Dasatinib (Src), Erlotinib (EGFR), and Saracatinib (Src) are examples. The intuition targets exactly the mechanism these drug classes address.

Intuition 16. What if cancer cells were marked as unfriendly so that surrounding cells reject them?

The most effective way to exclude someone socially is to make them unappealing. If cancer cells could be tagged such that surrounding normal cells reject them, they would be driven out.

Corresponding field: cell competition and the Flower protein. Eduardo Moreno’s group has shown that two isoforms of the Flower protein — Flower-Win and Flower-Lose — serve as molecular name tags indicating whether a cell is on the winning or losing side of a fitness comparison with its neighbors. Cells marked with Flower-Lose are actively eliminated by surrounding cells. Yasuyuki Fujita’s group has characterized Epithelial Defense Against Cancer (EDAC) at the molecular level, describing how normal epithelial cells actively extrude transformed cells. The intuition is exactly the mechanism these two fields pursue.

Intuition 17. What if cancer is an ancient evolutionary program that has woken up again?

The human body carries vestiges of its evolutionary past that are no longer in active use. The tailbone is one example. If cancer is such a vestige — an old genetic program that reawakens when it should stay silent — then the way we understand cancer shifts entirely.

Corresponding field: the atavism theory of cancer. The theory was formally proposed by Paul Davies (Arizona State University) and Charles Lineweaver (Australian National University) in the 2011 Physical Biology paper “Cancer tumors as Metazoa 1.0.” It was refined in 2021 as the Serial Atavism Model in BioEssays, and the 2017 PNAS paper from Trigos et al. used phylostratigraphy to show that genes expressed in tumors are biased toward ancient genes from the unicellular and early multicellular era. The Warburg effect — the tumor cell’s reliance on glycolysis even in the presence of oxygen — is interpreted as a reactivation of the metabolic program from an oxygen-poor unicellular past. Kimberly Bussey and Anneke Blackburn are among the researchers continuing work in this area. My “ancient reawakened gene” intuition matches the core frame of this theory at the level of vocabulary. What is especially worth noting is that Davies, as a theoretical physicist, was an outsider to the field of cancer biology, and has repeatedly said that he could propose this hypothesis precisely because he was not bound by the existing frames of cancer biology. This entry is perhaps the clearest example in this essay of how free thought from outside a specialized field can independently arrive at one of its most fundamental working hypotheses.

Intuition 18. What if the target site is occupied before the tumor cell arrives?

Metastatic sites are prepared to receive tumor cells before the tumor cells actually arrive. If that site can be pre-occupied, or if its environment can be altered in advance, the tumor cell cannot settle even when it arrives.

Corresponding field: the pre-metastatic niche. Stephen Paget’s 1889 “seed and soil” hypothesis is the conceptual starting point of the field. David Lyden’s group at Weill Cornell established the molecular biology of the pre-metastatic niche in 2005. The finding is that the primary tumor releases exosomes and soluble factors that arrive in advance at distant organs and remodel them into environments friendly to incoming tumor cells. Aptamers such as ESTA, which targets E-selectin, are being developed as tools to block pre-metastatic niche formation.

Intuition 19. Can an autologous tissue barrier be used to isolate a tumor?

If a tumor cannot be killed, can it at least be surrounded and isolated by autologous tissue that carries no risk of immune rejection?

Corresponding field: tumor encapsulation and Adipose Manipulation Transplantation (AMT). Some tumors naturally form fibrous capsules, and clinical data on colorectal liver metastases show that naturally encapsulated patients have notably lower recurrence rates. CAF-based encapsulation research was published in Nature Communications in 2023. Polymer-based encapsulation has been attempted using chitosan, alginate, and other materials. The 2025 Nature Biotechnology paper on Adipose Manipulation Transplantation reported an approach in which CRISPRa-enhanced autologous adipose tissue is implanted next to a tumor. This works more through nutrient competition than isolation, but it belongs to the same family as the use of autologous tissue. Proposal 2 at the front of this essay is a narrow variant in this field.

Intuition 20. What if we impose a cost on tumor cell migration itself, or lay traps along its route?

What if a cost could be imposed on the act of migration, or traps could be placed along migration routes such that tumor cells enter them voluntarily?

Corresponding field: migrastatic therapy and tumor traps. “Migrastatic intervention” is the formal term in the literature for a drug class that targets the cell migration machinery directly. Bispecific anti–IL-6/IL-8 antibodies, migrastatin analogs targeting fascin, ROCK inhibitors like Y-27632, the c-Met aptamer CSL1-II, and ICAM-1 aptamers all belong to this category. Tumor traps are a more intriguing field, exemplified by the Frontiers in Cell and Developmental Biology paper “Reversing the Tumor Target: Establishment of a Tumor Trap.” The strategy loads chemokines such as SDF-1 into a hydrogel scaffold so that tumor cells migrate into it voluntarily. The “pre-laid trap” intuition matches exactly the frame these two fields pursue.

Intuition 21. Can cancer resistance be transferred to or bestowed upon the next generation?

If the human species as a whole has not evolved strong cancer resistance, can the cancer resistance that other species have evolved be transferred to humans? Or can such resistance be bestowed in advance upon the next generation?

Corresponding field: mRNA cancer vaccines, Peto’s paradox, comparative oncology. The intuition connects to two fields at once. The first is personalized mRNA cancer vaccines. Moderna and Merck’s mRNA-4157 (V940, intismeran autogene) showed, in the KEYNOTE-942 Phase 2b trial in resected high-risk melanoma, a 49% reduction in recurrence or death and a 62% reduction in distant metastasis risk compared to Keytruda alone. The Phase 3 trial (NCT05933577) has enrolled 1,089 patients. BioNTech’s BNT111 (melanoma, FDA Fast Track) and BNT122 (pancreatic, autogene cevumeran) belong to the same class. The second is Peto’s paradox and cross-species comparative oncology. The paradox, raised by Richard Peto in 1977 — why do large animals not develop cancer proportionally to their far greater cell counts — was partly answered in 2015 with the discovery that elephants carry 20 copies of the TP53 gene (humans carry 2). PEEL Therapeutics, founded by Joshua Schiffman, is developing a gene therapy that delivers elephant TP53 retrogene in lipid nanoparticles, and according to AACR 2026 Abstract 5699, clinical trials in lung and colorectal cancer are now in progress. Vincent Lynch (University at Buffalo) discovered the CDKN2C duplication in bowhead whales, and the strong contact inhibition mechanisms of the naked mole rat are also under active investigation.

Intuition 22. What if the identity of a cancer cell is changed into that of another cell type?

A cancer cell is, after all, a specific type of cell. If its identity were changed into another cell type, without killing it, it would no longer function as cancer.

Corresponding field: differentiation therapy and transdifferentiation. The classic success case of differentiation therapy is ATRA (all-trans retinoic acid) for acute promyelocytic leukemia (APL). Introduced in the 1980s, ATRA differentiates undifferentiated leukemic cells into normal neutrophils and raised the 5-year survival rate of APL above 90%. A more striking case is the 2019 Cancer Cell paper “Gain Fat — Lose Metastasis” from Gerhard Christofori’s group at the University of Basel, which directly converted invasive breast cancer cells into adipocytes, suppressing both primary tumor invasion and metastatic colonization. The two drugs used — rosiglitazone (a diabetes drug, FDA approved) and trametinib (a MEK inhibitor, FDA approved) — are both already in clinical use. The converted adipocytes do not revert back into cancer cells. The 2025 Nature Biotechnology paper on Adipose Manipulation Transplantation further extends this idea.

Intuition 23. What if cancer cells could be made visually visible?

The reason a surgeon cannot precisely remove a tumor is that the boundary between normal and tumor tissue is not visible. If only the cancer cells could be made to glow visually, the surgeon could remove exactly those cells.

Corresponding field: fluorescence-guided surgery and tumor paint. The field began in 1948 and is now standard clinical practice. 5-ALA (Gleolan) is an orally administered fluorescent precursor that accumulates selectively in malignant glioma cells, is metabolized into protoporphyrin IX, and glows red under blue (405 nm) light. Walter Stummer (Düsseldorf) first introduced it clinically in 1998, Costas Hadjipanayis performed the first U.S. case in 2011, and the FDA approved it for glioma surgery in 2017. In a Phase 3 randomized controlled trial, the complete resection rate with 5-ALA was 65% versus 36% under white light alone. Tumor Paint (BLZ-100, tozuleristide) — and it is worth noting that my intuitive Korean phrasing matches the English name of the field — was developed by Jim Olson (Fred Hutchinson Cancer Research Center / Seattle Children’s Hospital). The drug conjugates chlorotoxin, derived from scorpion venom, to the Cy5.5 near-infrared fluorophore; it binds selectively to cancer cells, and Blaze Bioscience is running the clinical trials. Olson’s motivation came from his experience as a pediatric brain tumor surgeon watching young patients suffer due to the lack of precision in tumor resection. gGlu-HMRG, developed by the groups of Urano (University of Tokyo) and Hisataka Kobayashi (NIH), is a molecule sprayed onto suspicious tissue that turns fluorescent within 10 minutes via GGT enzyme activity. The same molecule (5-ALA) enables diagnosis (visualization) and therapy (photodynamic therapy) simultaneously, which means my “staining” intuition pointed at two distinct clinical applications in a single step. One further point worth noting is that the Korean phrasing I used for this intuition is conceptually identical to the English name Jim Olson gave to his field, “Tumor Paint.” Two people in different languages and cultures independently arrived at the same metaphor, which suggests the metaphor is not coincidental but arises naturally from the structure of the problem itself.

Meta-Analysis of the Pattern

Looking back at the twenty-five intuitions, it becomes clear that they are not random throws but operate within a consistent underlying model.

Domain distribution. The five domains from which I drew analogies are as follows:

First, analogies from daily life and interpersonal relations (social reasoning): Intuitions 6 (competition), 7 (mistaken identity), 10 (shock/force), 16 (exclusion), 22 (identity change).

Second, analogies from machines and computers (information-processing reasoning): Intuitions 3 (debug log), 4 (backup), 5 (selective reset), 14 (sensor disruption), 20 (traps).

Third, analogies from physics and nature (physical reasoning): Intuitions 8 (systemic cleansing), 12 (environmental control), 13 (polarity flip), 15 (structural removal), 19 (isolation), 23 (visualization).

Fourth, analogies from evolution and biology (lineage reasoning): Intuitions 11 (dormancy), 17 (ancestral genes), 21 (interspecies transfer).

Fifth, analogies from systems and control (hierarchical reasoning): Intuitions 1 (organ replacement), 2 (division control), 9 (upstream signal), 18 (pre-emption).

That five separate analogy domains operated simultaneously means the reasoning was not locked into a single metaphorical mode. This is the first feature of the thinking.

Temporal distribution. Looking at when the corresponding academic discoveries were made, the reasoning operated without bias along the time axis. Old findings it pointed to: Intuition 22 (ATRA in the 1980s), Intuition 23 (fluorescence surgery beginning in 1948), Intuition 6 (cell competition, 1975), Intuition 11 (tumor dormancy observed in 1934), Intuition 18 (the “seed and soil” hypothesis, 1889). Recent findings it pointed to: Intuition 17 (atavism theory, 2011), Intuition 9 (cancer neuroscience formally launched in 2019), Intuition 19’s neighbor (Adipose Manipulation Transplantation, 2025). Ongoing clinical trials it pointed to: Intuition 21 (PEEL Therapeutics 2026 trials, Moderna mRNA-4157 Phase 3), Intuition 10 (histotripsy FDA approval in 2023). The implication is straightforward. A mind that only tracks the latest news can only point at the latest discoveries. This exercise pointed simultaneously at ninety-year-old findings and ongoing clinical trials. The reasoning was operating at the level of essence, not fashion.

The freedom of being outside the field. The most important feature of this exercise comes from the outsider position itself. Academic thought operates in specialized vocabulary. When you think inside words like invadopodia, mechanosensing, transdifferentiation, thought is possible only within the boundaries those words define. A layperson’s thinking starts from rough everyday analogies: cut the structures, block the sensing, change the identity. Because these rough analogies are not precise, they can cross the boundaries between academic fields. That is why it was common for a single one of my intuitions to touch two or more research fields at once. Paul Davies once said that he could see what cancer biologists could not precisely because he was a physicist rather than a cancer biologist. This exercise was possible from the same kind of position — the freedom of standing outside the field.

The economics of thought. One further condition made this exercise possible. The spread of large language models has driven the cost, for a layperson, of searching and cross-checking cutting-edge literature in a specialized field close to zero. Ten years ago, a layperson with the intuition that “flipping the polarity of cancer cells would block invasion” would have needed university library access and a medical background to verify that this intuition corresponds to a sophisticated field built around Lgl, Dlg, and Scrib. Today, a few minutes of searching achieve the same verification. This means that laypeople’s intuitions — which previously stayed as spoken words or private thoughts — can now be immediately connected to and checked against the existing work of the field. This essay is one form of thought-work enabled by that new condition.

Closing

It should be clear from the start that this essay does not claim medical authority. But what it tries to show is one thing. In the face of one of humanity’s largest problems, the free thought of a layperson is not meaningless. That twenty-three out of twenty-five thoughts corresponded to active research fields is not well explained by chance. It is one example of how thinking — the most basic human capacity — can function differently in an era when information asymmetry is rapidly collapsing.

I am one citizen, one entrepreneur, and one person who thinks. If this essay causes even a single researcher to pause for a moment next to a field they are already working in and look at their own work from a different angle, the writing will have been worth doing. That is why I did it.

Hongik ingan (弘益人間) — to broadly benefit the human world.

Key Researchers and Groups Cited

About the Author

An Seungwon is the founder of Wonbrand and a Korean solo entrepreneur/maker. This essay is one result of his thinking work. It does not claim medical authority and welcomes academic scrutiny.

Contact: wonbrand.co.kr
Date: April 10, 2026

All cited fields, researchers, drugs, and clinical trials in this essay are based on peer-reviewed literature and verifiable primary sources such as ClinicalTrials.gov. This is a thought note, not an academic paper, and welcomes critical review from domain experts.